Literature DB >> 9204005

Ursodeoxycholic acid in cystic fibrosis-related liver disease: a systematic review.

K Cheng1, D Ashby, R Smyth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9204005      PMCID： PMC1296092          DOI： 10.1177/014107689709031S03

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   18.000


× No keyword cloud information.
  18 in total

1.  Liver and biliary problems in cystic fibrosis.

Authors:  M S Tanner
Journal:  J R Soc Med       Date:  1992       Impact factor: 5.344

2.  Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis.

Authors:  C Colombo; K D Setchell; M Podda; A Crosignani; A Roda; L Curcio; M Ronchi; A Giunta
Journal:  J Pediatr       Date:  1990-09       Impact factor: 4.406

3.  Biliary complications of cystic fibrosis.

Authors:  S O'Brien; M Keogan; M Casey; G Duffy; D McErlean; M X Fitzgerald; J E Hegarty
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

4.  Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells.

Authors:  J A Cohn; T V Strong; M R Picciotto; A C Nairn; F S Collins; J G Fitz
Journal:  Gastroenterology       Date:  1993-12       Impact factor: 22.682

5.  Cystic fibrosis: current survival and population estimates to the year 2000.

Authors:  J S Elborn; D J Shale; J R Britton
Journal:  Thorax       Date:  1991-12       Impact factor: 9.139

6.  Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

Authors:  R E Poupon; R Poupon; B Balkau
Journal:  N Engl J Med       Date:  1994-05-12       Impact factor: 91.245

7.  Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study.

Authors:  C Colombo; A Crosignani; M Assaisso; P M Battezzati; M Podda; A Giunta; L Zimmer-Nechemias; K D Setchell
Journal:  Hepatology       Date:  1992-10       Impact factor: 17.425

8.  Analysis of risk factors for the development of liver disease associated with cystic fibrosis.

Authors:  C Colombo; M G Apostolo; M Ferrari; M Seia; S Genoni; A Giunta; L P Sereni
Journal:  J Pediatr       Date:  1994-03       Impact factor: 4.406

9.  Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial.

Authors:  U Beuers; U Spengler; W Kruis; U Aydemir; B Wiebecke; W Heldwein; M Weinzierl; G R Pape; T Sauerbruch; G Paumgartner
Journal:  Hepatology       Date:  1992-09       Impact factor: 17.425

10.  Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts.

Authors:  C C Roy; A M Weber; C L Morin; G Lepage; G Brisson; I Yousef; R Lasalle
Journal:  J Pediatr Gastroenterol Nutr       Date:  1982       Impact factor: 2.839
View more
  2 in total

Review 1.  Ursodeoxycholic acid for cystic fibrosis-related liver disease.

Authors:  Katharine Cheng; Deborah Ashby; Rosalind L Smyth
Journal:  Cochrane Database Syst Rev       Date:  2017-09-11

2.  Systematic reviews in cystic fibrosis.

Authors:  R L Smyth; K Cheng; J Motley
Journal:  J R Soc Med       Date:  1998       Impact factor: 18.000
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.